Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine by India and Ukraine Haemato-oncology Group, Dharma Choudhary, Dinesh Bhurani, Iryna Kryachok, Iryna Koren’kova, Orest Tsyapka, Rahul Naithani, Viktor Kozlov, Amit Garg, Mykhaylo Morgunskyy, Yogesh Belagali, Namita Gupta, Shyam Prasad Akku

“…High-quality generics access will improve outcomes and support healthcare cost containment. Pharmacoeconomic studies and head-to-head trials are warranted to determine the cost-effectiveness and benefit of novel therapies in MM.…”
Get full text

Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience by Martina Maurelli, Giampiero Girolomoni, Paolo Gisondi

“…Background Pharmacoeconomic studies examining the cost-effectiveness of adalimumab biosimilars versus methotrexate in real-life settings are limited. …”
Get full text

Cost-effectiveness of therapeutic drug monitoring (TDM) of biologic treatment in rheumatic diseases: a narrative review by Konstantin Tachkov, Petya Nikolova, Rumyana Vitanska-Simeonova, Vladimira Boyadzhieva, Nikolay Stoilov, Guenka Petrova

“…The PubMed database was used to search for articles containing the key words ‘cost-effectiveness’ AND ‘therapeutic drug monitoring’ AND ‘rheumatology’ or ‘rheumatoid’ with no limits on year of publication. CHEERS pharmacoeconomic criteria were applied to review the robustness of the studies. …”
Get full text

CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC AMLODIPINE IN PATIENTS WITH MILD-TO-MODERATE ARTERIAL HYPERTENSION by N. A. Belolipetskiy, S. N. Tolpygina, J. B. Zverkov, V. V. Pisarev, I. E. Koltunov, V. G. Belolipetskaya, S. J. Martsevich

“…To study clinical equivalence of two amlodipines under the control of their plasma levels and evaluate their pharmacoeconomical efficacy in patients with arterial hypertension (AH).Material and methods. 31 patient with AH were included in the study (14 men and 17 women). 21 (66 %) patients had AH of 1 stage and 10 (34 %) patients had AH of 2 stage. …”
Get full text

Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil by R. Focaccia, D.C.M. Baraldo, M.L.G. Ferraz, A.L.C. Martinelli, F.J. Carrilho, F.L. Gonçales Jr., M.L.A. Pedroso, H.S.M. Coelho, M.A. Lacerda, C.E. Brandão, A.A. Mattos, L.G.C. Lira, I. Zamin Jr., J.O.P. Pinheiro, C.V. Tovo, C.T. Both, J.A.S. Soares, S. Dittrich

“…The finding that 65% of chronic hepatitis C patients have a body weight of 77 kg or less may have a positive pharmacoeconomic impact on the treatment of genotype 1 HCV patients with weight-based doses of peginterferon.…”
Get full text

Sviluppo e implementazione di un modello farmacoeconomico per valutare la costo efficacia di un ACE-inibitore nella prevenzione del rischio cardiovascolare by Sergio Iannazzo, Lorenzo Pradelli, Mario Eandi

“…In this article we present a flexible pharmacoeconomic model that permits the calculation of the marginal costeffectiveness of cardiovascular prevention with ramipril, a drug of the class of ACE-inhibitors. …”
Get full text

Cost-Effectiveness of a Hypothetical Gene Therapy for Alzheimer's Disease: A Markov Simulation Analysis by Thuy Chinh Kieu, Kevin Look

“…Thus, a comprehensive pharmacoeconomic assessment remains critical in pricing innovative therapy and determining coverage for patients in need. …”
Get full text

Bibliometric analysis and evidence of clinical efficacy and safety of digital pills by Olena Litvinova, Elisabeth Klager, Andy Wai Kan Yeung, Andy Wai Kan Yeung, Nikolay T. Tzvetkov, Oliver Kimberger, Oliver Kimberger, Maria Kletecka-Pulker, Maria Kletecka-Pulker, Harald Willschke, Harald Willschke, Atanas G. Atanasov, Atanas G. Atanasov

“…Nevertheless, the effects of digital pills have not yet been fully studied.Conclusion: Priority areas for future research are further randomized controlled clinical trials and meta-analyses, which are necessary for a high level (I level) of evidence for therapeutic applications of digital pills, as well as pharmacoeconomic studies.…”
Get full text

Diabetic retinopathy and age-related macular degeneration: a survey of pharmacoutilization and cost in Calabria, Italy by Damiana Scuteri, Ada Vero, Mariacristina Zito, Maria Diana Naturale, Giacinto Bagetta, Carlo Nucci, Paolo Tonin, Maria Tiziana Corasaniti

“…Due to the lack of epidemiologic and pharmacoeconomic evaluation in the local Calabria Region context, the present retrospective observational study focused on prevalence of DR and age-related macular degeneration, treatment and cost of therapy with ranibizumab in 870 patients arriving to clinical observation at the “Mater Domini” University Hospital in Calabria, Italy from January 2014 to June 2017. …”
Get full text

Real-life cost-effectiveness of benralizumab in patients with severe asthma by A. Padilla-Galo, A. J. García-Ruiz, R. Ch. Levy Abitbol, C. Olveira, F. Rivas-Ruiz, N. García-Agua Soler, M. Pérez Morales, B. Valencia Azcona, B. Tortajada-Goitia, I. Moya-Carmona, A. Levy-Naon

“…Conclusions All the pharmacoeconomic parameters analysed show that treatment with benralizumab is a cost-effective option as an add-on therapy in patients with refractory eosinophilic asthma.…”
Get full text

CURRENT TREATMENT OPTIONS FOR ANEMIA IN PREGNANT WOMEN (LECTURE) by V. M. Chernov, I. S. Tarasova

“…High efficiency, good tolerability of ferric carboxymaltose in the treatment of IDA are shown. Pharmacoeconomic analysis showed the feasibility of administration of ferric carboxymaltose in comparison with the drug of previous generation (iron sucrose). …”
Get full text

Unmet needs about iron deficiency in peritoneal dialysis: a Delphi consensus panel by Sandro Mazzaferro, Silvia D’Alonzo, Massimo Morosetti

“…Methods A list of 16 statements (48 items) was developed about four main topics: (1) approach to iron therapy in PD; (2) management experience about iron therapy in PD; (3) ESA and iron in PD; (4) pharmacoeconomic impact. Using the Delphi methodology, the survey was distributed online to 36 Italian nephrologists with expertise in PD, who rated their level of agreement with each item on a 5-point Likert scale. …”
Get full text

Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective by Weiyi Ni, Jia Liu, Yawen Jiang, Jing Wu

“…The base-case analysis used an annual discount rate of 5% for costs and benefits following the China Guidelines for Pharmacoeconomic Evaluations. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the model. …”
Get full text

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis by Peng-Fei Zhang, Peng-Fei Zhang, Dan Xie, Dan Xie, Qiu Li, Qiu Li

“…Background: The aim of this study is to evaluate the pharmacoeconomic profile of adding enzalutamide to first-line treatment for metastatic, hormone-sensitive prostate cancer (mHSPC) from the US and Chinese payers' perspectives.Materials and Methods: A Markov model with three health states: progression-free survival (PFS), progressive disease (PD), and death, was constructed. …”
Get full text

An evaluation of continuous subcutaneous infusions across seven NHS acute hospitals: is there potential for 48-hour infusions? by J. Baker, A. Dickman, S. Mason, M. Bickerstaff, R. Jackson, A. McArdle, I. Lawrence, F. Stephenson, N. Paton, J. Kirk, B. Waters, J. Ellershaw

“…Before a clinical feasibility study can be undertaken, a pharmacoeconomic assessment and robust chemical and microbiological stability data will be required, as will the assessment of the perceptions from clinical staff, patients and their families on the acceptability of such a change in practice.…”
Get full text

MODERN MODEL FORMATION OF DRUG PROVISION OF PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA IN KABARDINO-BALKARIA by A. A. Umirova, V. L. Adzhienko, T. I. Kabakova, E. A. Korzhavykh, V. V. Gatsan

“…Logical, retrospective, sociological, pharmacoeconomic, marketing, statistical and other analytical methods have been used. …”
Get full text

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma by Lina Benaniba, Benoit Tessoulin, Sabrina Trudel, Catherine Pellat-Deceunynck, Martine Amiot, Stéphane Minvielle, Pierre Antoine Gourraud, Sophie de Visme, Hervé Maisonneuve, Anne Lok, Steven Le Gouill, Philippe Moreau, Cyrille Touzeau

“…Additionally, the MYRACLE cohort will allow integrating the medical care of MM patients in a health and pharmacoeconomic perspective.…”
Get full text

ANALISIS BIAYA KEMOTERAPI PADA PASIEN RAWAT INAP KANKER PAYUDARA PESERTA JKN DI RSUD ULIN BANJARMASIN by Noor Aisyah, Tri Murti Andayani, Diah Ayu Puspandari

“…This research was a pharmacoeconomic analysis research with a hospital perspective on direct medical costs, and the data was taken retrospectively. …”
Get full text

Safety and efficiency of the minimalistic and precise approachfor transcatheter aortic valve implantation (TAVI) comparedto the standard one by I. Petrov, Z. Stankov, P. Polomski, J. Stoykova, A. Cherneva, D. Boychev, M. Bonev

“…The main focus of this manuscript is improvement of the procedure results, quality of life and comfort of the patients, while providing a better pharmacoeconomic profile.The minimalistic and precise protocol of implantation and the vascular device closure are thoroughly described. …”
Get full text

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci by Carmen Hidalgo-Tenorio, David Vinuesa, Antonio Plata, Pilar Martin Dávila, Simona Iftimie, Sergio Sequera, Belén Loeches, Luis Eduardo Lopez-Cortés, Mari Carmen Fariñas, Concepción Fernández-Roldan, Rosario Javier-Martinez, Patricia Muñoz, Maria del Mar Arenas-Miras, Francisco Javier Martínez-Marcos, Jose Maria Miró, Carmen Herrero, Elena Bereciartua, Samantha E. De Jesus, Juan Pasquau

“…Abstract Objectives To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. Methods A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. …”
Get full text